Resultado final
Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC
Highly purified antibody therapy for preclinical studiesCharacterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed
Antibody DNA sequence of lead candidate(s)Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners
Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines
Buscando datos de OpenAIRE...
Se ha producido un error en la búsqueda de datos de OpenAIRE
No hay resultados disponibles